| 摘要: |
| 嵌合抗原受体(chimeric antigen receptor, CAR)是一种人工修饰的T细胞表面受体,它可以模拟天然的T细胞受体(T cell receptor, TCR)的功能。使用转基因技术可以在T细胞表面稳定表达CAR。CAR修饰T细胞(CAR-T细胞)利用抗体的肿瘤特异性识别能力,靶向发挥T细胞的效应功能。目前CAR-T细胞在临床治疗白血病、淋巴瘤、黑素瘤等恶性肿瘤中取得了令人鼓舞的效果。但由于实体肿瘤的某些特点,CAR-T细胞在临床治疗实体肿瘤的实践中存在部分障碍。随着研究的深入,三代CAR-T细胞、双重特异性CAR-T细胞等的应用将为CAR-T细胞临床治疗实体肿瘤开拓道路。本文就近年来CAR-T细胞在实体肿瘤中的应用作一综述。 |
| 关键词: 嵌合抗原受体 T淋巴细胞 实体肿瘤 免疫疗法 |
| DOI：10.16781/j.0258-879x.2016.04.0482 |
| 投稿时间：2015-09-12修订日期：2015-10-28 |
| 基金项目: |
|
| Clinical application of chimeric antigen receptor-engineered T cells in treatment of solid tumors |
| MA Yun-han,PAN Yu-fei,DONG Li-wei,TAN Ye-xiong* |
(International Co-operation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, China
*Corresponding author) |
| Abstract: |
| The chimeric antigen receptor (CAR) is an artificial T cell surface receptor that simulates the physiological functions of the native T cell receptor (TCR). With gene transfer technologies, T cells can be genetically modified to stably express CAR on their surface. The CAR-T cells have a combined advantage of antibody tumor specificity and T cells' effector function. Today the clinical trials with leukemia,lymphoma and melanoma have seen impressive results, but the clinical use of CAR-T cells for solid tumors has faced some challenges due to certain characteristics of solid tumors. In the future the third generation CAR-T cells, dual-specificity CAR-T cells and some new discoveries will pave a way for the application of CAR-T cells for solid tumors. In this paper, we reviewed the application of CAR-T cells for treatment of solid tumors in recent years. |
| Key words: chimeric antigen receptor T-lymphocytes solid tumor immunotherapy |
